Orthocell (OCC) Short Interest
Orthocell (ASX:OCC) had 0.30% of shares reported as short positions as of 24 Aug 2026, representing 829,244 shares. Orthocell operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Orthocell
Orthocell is a leader in the regenerative medicine sector, focusing on innovative treatments for chronic degenerative diseases and injuries. The company specializes in developing collagen medical devices and cell therapies that leverage the body's natural repair mechanisms. Orthocell's products are designed to enhance surgical repair and promote tissue regeneration, positioning it as a pioneer in the biotechnology and life sciences industry.
Short position
Orthocell (ASX:OCC) has 0.30% of its shares on issue reported as short positions as of 24 Aug 2026, or about 829,244 shares. Over the past 30 days that figure has fallen 0.07 percentage points, and over 90 days it has fallen 0.17 percentage points. Its highest recorded short interest was 0.89% in December 2025. OCC is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Weekly context: The 10 most shorted ASX stocks — Week 35, 2026.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4OCC intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Short interest history & FAQ
Company
AI-generated research profile of Orthocell
Latest OCC news
All news- What’s Next for Orthocell (ASX:OCC) After Growth Update?
kalkine
- Why Does Orthocell (ASX:OCC) Matter Now Among ASX Healthcare Stocks?
kalkine
- Orthocell Canaccord Genuity Conference Live Webcast
asx
- Orthocell (ASX:OCC) Delivers Record Revenue While US Remplir Growth Remains Key Focus - Kalkine
googlenews
- Orthocell to Present at Canaccord Growth Conference
asx
About
website
address
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss OCC
Start a research thread or post the first pulse update